Summit Therapeutics Inc.
Advancing a Phase 3 bispecific antibody for lung cancer and other solid tumors.
SMMT | US
Overview
Corporate Details
- ISIN(s):
- US86627T1088
- LEI:
- Country:
- United States of America
- Address:
- 601 BRICKELL KEY DRIVE, 33131 MIAMI
- Website:
- https://www.smmttx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies in oncology. The company aims to address serious unmet medical needs and improve the quality and potential duration of life for patients with difficult cancer diagnoses. Its lead asset is ivonescimab (SMT112), a potential first-in-class, investigational bispecific antibody that combines the effects of immunotherapy (PD-1 blockade) and anti-angiogenesis (VEGF blockade) into a single molecule. Summit is advancing ivonescimab through multiple Phase 3 clinical trials, with an initial focus on non-small cell lung cancer (NSCLC) and plans for expansion into other solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Summit Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Summit Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Summit Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
